Armata Pharmaceuticals, Inc. - Common Stock, $0.01 par value (ARMP) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2019 to Q4 2025

Type / Class
Equity / Common Stock, $0.01 par value
Symbol
ARMP on NYSE
Shares outstanding
66,587,586
Price per share
$6.48
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
758,320
Total reported value
$2,268,276
% of total 13F portfolios
0%
Share change
+24,505
Value change
+$89,233
Number of holders
26
Price from insider filings
$6.48
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Armata Pharmaceuticals, Inc. - Common Stock, $0.01 par value (ARMP) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Innoviva, Inc. 83% -2.2% $123,137,759 -$19,337,976 55,467,459 -14% Innoviva, Inc. 11 Aug 2025

As of 30 Sep 2025, 26 institutional investors reported holding 758,320 shares of Armata Pharmaceuticals, Inc. - Common Stock, $0.01 par value (ARMP). This represents 1.1% of the company’s total 66,587,586 outstanding shares.

Institutional Holders of Armata Pharmaceuticals, Inc. - Common Stock, $0.01 par value (ARMP) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 41,059 $274,246 +$40,009 $6.48 2
2025 Q3 758,320 $2,268,276 +$89,233 $2.98 26
2025 Q2 733,816 $1,394,405 +$8,714 $1.90 28
2025 Q1 740,370 $1,080,988 -$948,245 $1.46 25
2024 Q4 1,388,825 $2,569,389 +$5,735 $1.85 22
2024 Q3 1,383,530 $3,279,033 -$52,091 $2.37 21
2024 Q2 1,404,321 $3,861,965 -$42,263 $2.75 21
2024 Q1 1,419,594 $5,934,185 +$548,366 $4.18 23
2023 Q4 1,288,743 $4,173,688 +$25,720 $3.24 24
2023 Q3 1,281,850 $3,845,146 +$326,709 $3.00 22
2023 Q2 1,185,412 $1,350,731 -$74,310 $1.14 20
2023 Q1 1,234,381 $2,061,949 -$89,077 $1.67 21
2022 Q4 1,303,324 $1,614,012 -$228,182 $1.24 25
2022 Q3 1,358,062 $5,732,000 +$37,042 $4.22 15
2022 Q2 1,349,314 $5,246,000 -$7,456 $3.88 15
2022 Q1 1,351,550 $6,609,000 +$136,417 $4.89 15
2021 Q4 1,322,160 $7,245,000 +$737,780 $5.48 15
2021 Q3 1,192,207 $4,315,000 +$124,783 $3.62 16
2021 Q2 1,156,685 $4,591,000 -$184,271 $3.97 16
2021 Q1 1,175,413 $5,620,000 +$1,487,592 $4.79 18
2020 Q4 868,848 $2,592,000 -$12,512 $2.99 14
2020 Q3 874,709 $2,790,000 +$50,948 $3.19 15
2020 Q2 857,827 $3,363,000 +$2,663,432 $3.92 14
2020 Q1 178,235 $554,000 +$45,037 $3.10 13
2019 Q4 163,127 $531,000 +$103,852 $3.27 11
2019 Q3 131,083 $485,000 +$39,624 $3.69 10
2019 Q2 118,107 $474,000 -$162,065 $4.02 8
2019 Q1 157,638 $47,000 +$47,000 $0.30 1